Results 11 to 20 of about 26,042 (243)

Evaluation of the anticancer activity of dipyridamole and Imatinib mesylate compounds against breast cancer cell line and related biochemical and genetic changes [PDF]

open access: yesJournal of Bioscience and Applied Research, 2021
Imatinib mesylate and dipyridamole were antineoplastic targeted chemotherapeutic agents, and it is here evaluating the anticancer of imatinib mesylate and dipyridamole compounds against MDA-MB231 breast cancer cell line in-vitro and the related cell ...
Rania El-Leithy   +3 more
doaj   +1 more source

Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro. [PDF]

open access: diamondOncol Lett, 2019
Kroschwald LM   +7 more
europepmc   +3 more sources

Imatinib mesylate in chordoma [PDF]

open access: bronzeCancer, 2004
AbstractBACKGROUNDTo the authors' knowledge, no effective medical therapy currently is available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting platelet‐derived growth factor receptor‐β (PDGFRB), BCR‐ABL, and KIT.METHODSSix patients with advanced chordoma were treated with imatinib mesylate at a dose of 800 mg daily ...
Paolo G. Casali   +17 more
openalex   +3 more sources

Imatinib-induced hepatitis treated by corticosteroids in a patient with metastatic gastrointestinal stromal tumor [PDF]

open access: yesYeungnam University Journal of Medicine, 2019
Imatinib mesylate is currently used as the first-line treatment for metastatic gastrointestinal stromal tumors (GISTs). Imatinib-induced hepatotoxicity in patients with GIST is very rare.
Min Kyu Kang   +2 more
doaj   +1 more source

Paraneoplastic hypoglycaemia secondary to IGF-2 secretion from a metastatic gastrointestinal stromal tumour [PDF]

open access: yes, 2020
We report the case of a 79-year-old male with previous history of non-Hodgkin's lymphoma in remission, who presented acutely to the Accident and Emergency department with recurrent episodes of hypoglycaemia.
Dimitriadis, Georgios K.   +9 more
core   +1 more source

Erythema following imatinib mesylate [PDF]

open access: bronzeBritish Journal of Haematology, 2003
Edward Duncan, Kavita Raj, Ghulam Mufti
openalex   +3 more sources

Imatinib-induced interstitial pneumonitis – a literature review and case report [PDF]

open access: yes, 2020
Imatinib is generally well tolerated, with mild common side effects such as nausea and vomiting, diarrhea, muscle cramps, fatigue, skin rash and edema; however, pulmonary complications are uncommon. A 73-year-old woman undergoing one month treatment with
Ciulei, George   +12 more
core   +2 more sources

Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitro. [PDF]

open access: yes, 2011
OBJECTIVE: The origin of the mesenchymal cells responsible for the intimal fibrosis in systemic sclerosis (SSc) has not been fully identified. The present study was undertaken to investigate whether subendothelial mesenchymal cells may emerge through ...
Jimenez, Sergio A., Li, zhaodong
core   +2 more sources

Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models.

open access: yesPLoS ONE, 2014
Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the importance of exploring new therapeutic methods.
Bérengère Gobin   +7 more
doaj   +1 more source

SUCCINATE DEHYDROGENASE SUBUNIT B DEFICIENT PEDIATRIC GIST

open access: yesHematology, Transfusion and Cell Therapy, 2022
Case report Gastrointestinal stromal tumors (GISTs) occur exceedingly rare in children and adolescents. Eighty five percent of pediatric GISTs and 15 % of adult GISTs lack oncogenic mutations in KIT and PDGFRA.
Melek Yaman Ortakoylu   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy